Antibiotic resistance - One Health Policy Integration

Global Strategies to Combat Antimicrobial Resistance Introduction Antimicrobial resistance (AMR) is a complex, global health crisis that cannot be solved by any single country, institution, or sector working alone. The policy response to AMR has evolved into a comprehensive, multi-faceted approach that involves international coordination, domestic legislation, innovative incentive structures, and integrated surveillance across human health, animal agriculture, and environmental systems. This section explores how global policy frameworks attempt to slow the emergence of resistance, monitor its spread, and preserve the effectiveness of existing and future antimicrobial drugs. The One Health Approach to Surveillance and Prevention Understanding One Health Integration The One Health approach recognizes that antimicrobial resistance spreads across three interconnected domains: human medicine, animal agriculture, and the environment. Rather than monitoring resistance separately in each sector, One Health surveillance integrates data from all three domains to provide a comprehensive view of how resistance emerges and spreads. This integration is critical because resistance doesn't stay isolated. Resistant bacteria from livestock can contaminate food and water supplies. Pharmaceutical waste from drug manufacturing plants can enter aquatic ecosystems. Hospitals discharge resistant organisms into sewage systems. By monitoring antibiotic consumption and resistance trends across all these sources, policymakers can identify where resistance originates and how it moves through populations. Key One Health Interventions Banning non-therapeutic antibiotic use in animals is one of the most impactful One Health policies. The European Union implemented this ban in 2006, prohibiting the use of medically important antibiotics for growth promotion in livestock. When animals receive antibiotics primarily to promote growth rather than treat disease, they continuously shed resistant bacteria into the environment. Eliminating this practice directly reduces the selective pressure that drives resistance emergence in farm animals. Environmental mitigation addresses the "hidden" pathways of resistance spread. Pharmaceutical waste from manufacturing sites, hospital wastewater, and agricultural runoff all contain antibiotics and resistant bacteria. Reducing pharmaceutical discharge into water systems and properly managing wastewater from hospitals, farms, and drug-manufacturing facilities curtails the environmental reservoir of antimicrobial resistance. The aquatic environment can act as a persistent reservoir where resistance genes accumulate and spread among bacterial species. Developing and incentivizing alternatives shifts the focus from relying solely on antibiotics. Vaccines can prevent infections before they start. Bacteriophages (viruses that infect bacteria) offer targeted antimicrobial approaches. Novel antibiotics with new mechanisms of action can overcome existing resistance mechanisms. Policy support for these alternatives reduces pressure on traditional antibiotic use. International Policy Framework and Global Coordination The WHO Global Action Plan In 2015, the World Health Organization published its Global Action Plan on Antimicrobial Resistance, which provides a blueprint for countries worldwide. The plan outlines five key objectives: Awareness and understanding of AMR Surveillance systems to monitor resistance trends Infection prevention and stewardship to reduce unnecessary antibiotic use Research and development of new antimicrobials and diagnostics Funding to support implementation The United Nations Inter-Agency Coordination Group (IACG) strengthens this framework by explicitly advocating a One Health approach and coordinating action across UN agencies that address different sectors—human health, animal health, and environmental concerns. International Legal Agreements and Accountability Recognizing that no single nation can solve a global problem, international bodies are developing binding legal frameworks for AMR, drawing lessons from successful international agreements like the Paris Climate Agreement. These frameworks would establish: Specific commitments from each nation to reduce antibiotic use, strengthen surveillance, and implement stewardship Majority-vote decision-making rules to allow consensus decision-making among diverse nations Independent scientific panels that provide objective advice without political bias Assistance mechanisms to help low- and middle-income countries implement antimicrobial resistance measures Sanctions for non-compliance to enforce accountability The UN General Assembly has convened high-level meetings specifically dedicated to AMR, setting global targets for reducing antibiotic-related deaths and establishing antimicrobial stewardship programs. Funding and Research Priorities International investment in new antibiotics, diagnostics, and vaccines is essential, yet pharmaceutical companies have historically underinvested in antibiotic development. Since the mid-1980s, the focus has shifted toward chronic-disease drugs, which generate steady profits over many years. Antibiotics, by contrast, are designed to be used briefly and, ideally, to become obsolete as stewardship prevents resistance. This misalignment between public health needs and profit incentives requires policy intervention through government funding, grants, and tax incentives. The WHO Fungal Priority List is one example of strategic research prioritization. By identifying fungal pathogens as public health threats requiring urgent attention, the WHO guides research funding and drug development efforts toward gaps in treatment options. The U.S. National Action Plan: A Case Study in Domestic Policy Strategic Framework and National Goals The National Action Plan for Combating Antibiotic-Resistant Bacteria (with versions covering 2015-2020 and 2023-2028) represents the United States' comprehensive domestic response. The plan established five national goals: Slow the emergence of resistant bacteria through stewardship and infection prevention Strengthen One-Health surveillance to monitor resistance across human, animal, and environmental domains Advance rapid diagnostics to enable faster, more targeted treatment decisions Accelerate research on new therapeutics, vaccines, and alternatives to antibiotics Improve international collaboration to coordinate global responses Concrete Targets and Benchmarks The National Action Plan distinguished itself by setting measurable targets with specific deadlines. By 2020, the plan aimed to achieve: Elimination of medically important antibiotics for growth promotion in food-producing animals—removing a major source of resistant bacteria in the food supply Establishment of antimicrobial stewardship programs in all acute-care hospitals—ensuring that every hospitalized patient receives antibiotics only when clinically appropriate 50% reduction in inappropriate outpatient antibiotic prescriptions and a 20% reduction in inappropriate inpatient prescriptions—directly addressing overprescribing in healthcare Creation of state antimicrobial-resistance prevention programs in all 50 states—building infrastructure for surveillance and control at the local level These targets translate abstract goals into concrete actions that can be monitored and evaluated. Current Burden of Resistance in the United States The stakes for this policy work are enormous. According to the 2023 Centers for Disease Control and Prevention report: More than 2.8 million antibiotic-resistant infections occur in the United States annually At least 35,000 deaths per year result from antibiotic-resistant infections The most concerning resistant pathogens include: Carbapenem-resistant Enterobacteriaceae (CRE): Gram-negative bacteria resistant to nearly all antibiotics Methicillin-resistant Staphylococcus aureus (MRSA): Among the most prevalent hospital-acquired infections Clostridioides difficile (C. difficile): A spore-forming bacterium that causes severe infections, particularly after disruption of normal gut flora by antibiotics The COVID-19 Pandemic and Resurgence of Resistance The COVID-19 pandemic unexpectedly accelerated antimicrobial resistance trends. Widespread antibacterial and antifungal use in critically ill COVID-19 patients, combined with disrupted infection control practices and overwhelmed healthcare systems, created ideal conditions for resistance emergence. A 2021 CDC analysis found a sharp rise in healthcare-associated infections caused by resistant organisms in COVID-19 patients—a concerning trend that persisted into 2023. In response, the Get Ahead of Sepsis campaign expanded in 2023 to raise awareness of AMR's role in sepsis and promote judicious antibiotic use, recognizing that sepsis mortality depends on both rapid treatment and preventing resistance that would render treatment ineffective. Policy Implementation Tools and Mechanisms Innovative Payment Models One of the most creative policy approaches addresses the fundamental economic problem: pharmaceutical companies have little financial incentive to develop new antibiotics because these drugs are used briefly and—if stewardship succeeds—used rarely. The PASTEUR Act proposes a subscription-based payment model that decouples antibiotic compensation from sales volume. Instead of paying based on how many doses are sold, governments would pay pharmaceutical companies a subscription fee for maintaining a portfolio of novel antimicrobials. This approach incentivizes development while simultaneously supporting stewardship programs—the fewer patients who receive the antibiotic, the better. Delinked payment models extend this concept: developers are compensated based on the value of their antimicrobial (its novelty, spectrum of activity, and effectiveness against resistant pathogens) rather than sales volume. This explicitly preserves novel agents for rare, resistant infections rather than encouraging widespread use that would rapidly breed resistance. Surveillance and Monitoring Systems Effective policy requires data. Resistance-tracking systems strengthen laboratory capacity in hospitals and public health agencies to: Regularly test clinical isolates for antibiotic susceptibility Identify emerging resistance patterns in real time Report data to national surveillance networks Enforce guidelines for appropriate antibiotic use based on local resistance patterns These systems transform resistance from an abstract concept into quantifiable, traceable epidemiological data. One-Health Surveillance Networks Beyond human medicine, integrated surveillance systems collect data from: Animal agriculture: Antibiotic use in livestock and resistance in farm animals Food systems: Resistance in food animals and contamination in food products Wastewater: Resistance prevalence in municipal and hospital waste streams Environmental samples: Resistance in surface waters, soil, and other ecosystems Global partnerships such as the World Health Organization's antimicrobial resistance coordination group facilitate information sharing among nations, creating networks that can detect and respond to emerging resistance threats faster than any single country could alone. Innovation, Economics, and Structural Incentives The Pharmaceutical Industry Problem A fundamental challenge in combating AMR stems from misaligned economic incentives. Since the mid-1980s, pharmaceutical companies have systematically shifted investment away from antibiotic research toward chronic-disease drugs (diabetes, hypertension, cancer). Here's why: Chronic-disease medications are taken daily for years or decades, generating reliable revenue Antibiotics are taken for days or weeks, generating minimal lifetime revenue Successful stewardship (goal: reduced antibiotic use) directly reduces antibiotic sales Developing a novel antibiotic requires enormous R&D investment with uncertain return This structural misalignment means that market forces alone will not produce the new antibiotics that resistance evolution demands. Policy intervention through novel payment structures is necessary. Delinked Payment Innovation Delinked payment models represent a policy innovation that directly addresses this problem. Rather than pharmaceutical companies earning money proportional to how much antibiotic they sell, they receive compensation based on the intrinsic value of their discovery. A company that develops a novel antibiotic against a highly resistant pathogen receives substantial payment—regardless of whether the antibiotic is used rarely or frequently. In fact, rare use (indicating preservation for serious infections) might be rewarded rather than penalized. This model fundamentally realigns incentives: companies profit by discovering valuable antimicrobials, not by maximizing sales volume. <extrainfo> Legal Frameworks for Global Coordination Scholars increasingly advocate for a binding global legal framework that would: Coordinate prevention and control of antimicrobial resistance across nations Establish standardized stewardship protocols Create mechanisms for technology transfer and capacity building Allow coordinated response to emerging resistance threats Such a framework would resemble successful international agreements (nuclear non-proliferation treaties, climate agreements) that establish binding obligations and verification mechanisms. </extrainfo> Measuring Success: Challenges in Policy Evaluation Why Economic Evaluation Is Difficult Evaluating the success of antimicrobial resistance policies presents unique challenges. Most benefits appear only in the distant future: A stewardship program implemented today prevents resistance that would otherwise emerge years from now Reducing antibiotic use in animals today saves future hospital patients from resistant infections tomorrow The mortality prevented may never be directly observable (we don't see people who didn't die from resistant infections) Traditional cost-benefit analysis struggles with this temporal displacement. Using Mathematical Models To address this challenge, public health researchers use mathematical modeling—similar to models used in other infectious disease contexts. These models: Simulate bacterial populations and resistance emergence over time Estimate how specific policy interventions reduce future resistance Calculate long-term costs avoided and lives saved Help policymakers understand when short-term costs (e.g., higher antibiotic prices from new payment models) justify long-term benefits However, accurate modeling requires understanding precisely how antimicrobial resistance spreads between populations, persists in environments, and responds to interventions. This knowledge remains incomplete, making predictions uncertain. <extrainfo> The challenge of measuring policy effectiveness highlights why more research is needed to understand antimicrobial resistance transmission. Better models would enable better predictions of policy outcomes and more effective resource allocation. </extrainfo> Summary: A Coordinated Global Response Combating antimicrobial resistance requires coordination across multiple levels and sectors: International frameworks (WHO Global Action Plan, UN coordination) set goals and encourage alignment National policies (like the U.S. National Action Plan) translate global objectives into specific, measurable domestic actions Economic incentives (delinked payments, subscription models) realign pharmaceutical industry interests with public health needs Integrated surveillance (One Health approach) monitors resistance emergence across human, animal, and environmental domains Targeted interventions (banning non-therapeutic antibiotics, environmental mitigation) reduce resistance sources Innovation support (research funding, new diagnostics, alternatives) creates solutions beyond traditional antibiotics No single strategy suffices. Resistance evolution is inevitable, but policy can slow its emergence, preserve the effectiveness of existing drugs, and accelerate development of new antimicrobial tools.